44 employees
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
2002
$23M
from 3 investors over 3 rounds
Advaxis, Inc. raised $23M on February 19, 2015
Investors: Sectoral Asset Management, Adage Capital Management and T. Rowe Price